Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of huntington's disease

Human Molecular Genetics

Volumn 22, Issue 17, 2013, Pages 3485-3497

  Lundh, Sofia Hult ^a   NNilsso, Nathalie ^a   Soylu, Rana ^a   Kirik, Deniz ^a   Petersén, Åsa ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; MUTANT PROTEIN; NEUROPEPTIDE Y; OREXIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR 3; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN NERVE CELL; CELL POPULATION; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; ELEVATED PLUS MAZE TEST; EXPERIMENTAL MODEL; EXPERIMENTAL TEST; FEMALE; GENE EXPRESSION REGULATION; HUNTINGTON CHOREA; HYPOTHALAMUS; HYPOTHALAMUS FUNCTION DISORDER; LONG TERM CARE; MALE; MOUSE; NEUROBIOLOGY; NONHUMAN; PORSOLT FORCED SWIM TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUCROSE PREFERENCE TEST; TRANSGENIC MOUSE;

EID: 84881580793     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt203     Document Type: Article

References (85)

1. HDCRG. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971-983.
2. Zuccato, C., Valenza, M. and Cattaneo, E. (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev., 90, 905-981.
3. Ross, C.A., Tabrizi, S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol., 10, 83-98.
4. Reiner, A., Dragatsis, I., Dietrich, P. (2011) Genetics and neuropathology of Huntington's disease. Int. Rev. Neurobiol., 98, 325-372.
5. Vonsattel, J.P., Keller, C., Cortes Ramirez, E.P. (2011) Huntington's disease - neuropathology. Handb. Clin. Neurol., 100, 83-100.
6. Sturrock, A., Leavitt, B.R. (2010) The clinical and genetic features of Huntington disease. J. Geriatr. Psychiatry Neurol., 23, 243-259.
7. Duff, K., Paulsen, J.S., Beglinger, L.J., Langbehn, D.R., Stout, J.C. (2007) Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol. Psychiatry, 62, 1341-1346.
8. van Duijn, E., Kingma,E.M., van der Mast, R.C. (2007) Psychopathology in verified Huntington's disease gene carriers. J. Neuropsychiatry Clin. Neurosci., 19, 441-448.
9. Epping, E.A., Paulsen, J.S. (2011) Depression in the early stages of Huntington disease. Neurodegener. Dis. Manag., 1, 407-414.
10. Jensen, P., Sorensen, S.A., Fenger, K., Bolwig, T.G. (1993) A study of psychiatric morbidity in patients with Huntington's disease, their relatives, and controls. Admissions to psychiatric hospitals in Denmark from 1969 to 1991. Br. J. Psychiatry, 163, 790-797.
11. Julien, C.L., Thompson, J.C., Wild, S., Yardumian, P., Snowden, J.S., Turner, G., Craufurd, D. (2007) Psychiatric disorders in preclinical Huntington's disease. J. Neurol. Neurosurg. Psychiatry, 78, 939-943.
12. Kingma, E.M., van Duijn, E., Timman,R., van der Mast, R.C., Roos, R.A. (2008) Behavioural problems in Huntington's disease using the Problem Behaviours Assessment. Gen. Hosp. Psychiatry, 30, 155-161.
13. van Duijn, E., Kingma, E.M., Timman, R., Zitman, F.G., Tibben, A., Roos, R.A., van der Mast, R.C. (2008) Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first-degree relatives. J. Clin. Psychiatry, 69, 1804- 1810.
14. Menalled, L., El-Khodor, B.F., Patry, M., Suarez-Farinas, M., Orenstein, S.J., Zahasky, B., Leahy, C., Wheeler, V., Yang, X.W., MacDonald, M. et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis., 35, 319-336.
15. Pang, T.Y., Du, X., Zajac, M.S., Howard, M.L., Hannan, A.J. (2009) Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum. Mol. Genet., 18, 753-766.
16. Pouladi, M.A., Stanek, L.M., Xie, Y., Franciosi, S., Southwell, A.L., Deng, Y., Butland, S., Zhang, W., Cheng, S.H., Shihabuddin, L.S. et al. (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet., 21, 2219-2232.
17. Renoir, T., Zajac, M.S., Du, X., Pang, T.Y., Leang, L., Chevarin, C., Lanfumey, L., Hannan, A.J. (2011) Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression. PLoS ONE, 6, e22133.
18. Pouladi, M.A., Graham, R.K., Karasinska, J.M., Xie, Y., Santos, R.D., Petersen, A., Hayden, M.R. (2009) Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain, 132, 919-932.
19. Abada, Y.S., Schreiber, R., Ellenbroek, B. (2013) Motor, emotional and cognitive deficits in adult BACHD mice: A model for Huntington's disease. Behav. Brain Res., 238, 243-251.
20. Lundh, S.H., Soylu, R., Petersen, A. (2012) Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse. PLoS ONE, 7, e51168.
21. Southwell, A.L., Warby, S.C., Carroll, J.B., Doty, C.N., Skotte, N.H., Zhang, W., Villanueva, E.B., Kovalik, V., Xie, Y., Pouladi, M.A., et al. (2013) A fully humanized transgenic mouse model of Huntington disease. Hum. Mol. Genet., 22, 18-34.
22. Hickey, M.A., Kosmalska, A., Enayati, J., Cohen, R., Zeitlin, S., Levine, M.S., Chesselet, M.F. (2008) Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience, 157, 280-295.
23. Renoir, T., Pang, T.Y., Zajac, M.S., Chan, G., Du, X., Leang, L., Chevarin, C., Lanfumey, L., Hannan, A.J. (2012) Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise. Br. J. Pharmacol., 165, 1375-1389.
24. Krishnan, V., Nestler, E.J. (2010) Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry, 167, 1305-1320.
25. Gabery, S., Murphy, K., Schultz, K., Loy, C.T., McCusker, E., Kirik, D., Halliday, G., Petersen, A. (2010) Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol., 120, 777-788.
26. Petersen, A., Gil, J., Maat-Schieman, M.L., Bjorkqvist, M., Tanila, H., Araujo, I.M., Smith, R., Popovic, N., Wierup, N., Norlen, P., et al. (2005) Orexin loss in Huntington's disease. Hum. Mol. Genet., 14, 39-47.
27. Soneson, C., Fontes, M., Zhou, Y., Denisov, V., Paulsen, J.S., Kirik, D., Petersen, A. (2010) Early changes in the hypothalamic region in prodromal Huntington disease revealed byMRIanalysis. Neurobiol. Dis., 40, 531-543.
28. Aziz, A., Fronczek, R., Maat-Schieman, M., Unmehopa, U., Roelandse, F., Overeem, S., van Duinen, S., Lammers, G.J., Swaab, D., Roos, R. (2008) Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol., 18, 474-483.
29. Aziz, N.A., Pijl, H., Frolich, M., van der Graaf, A.W., Roelfsema, F., Roos, R.A. (2009) Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J. Clin. Endocrinol. Metab., 94, 1223-1228.
30. Bjorkqvist, M., Leavitt, B.R., Nielsen, J.E., Landwehrmeyer, B., Ecker, D., Mulder, H., Brundin, P., Petersen, A. (2007) Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Mov. Disord., 22, 1952-1954.
31. Gray, M., Shirasaki, D.I., Cepeda, C., Andre, V.M., Wilburn, B., Lu, X.H., Tao, J., Yamazaki, I., Li, S.H., Sun, Y.E., et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci., 28, 6182- 6195.
32. Nestler, E.J., Hyman, S.E. (2010) Animal models of neuropsychiatric disorders. Nat. Neurosci., 13, 1161-1169.
33. Cryan, J.F., Markou, A., Lucki, I. (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci., 23, 238-245.
34. Harkin, A., Houlihan, D.D., Kelly, J.P. (2002) Reduction in preference for saccharin by repeated unpredictable stress in mice and its prevention by imipramine. J. Psychopharmacol., 16, 115-123.
35. Porsolt, R.D., Le Pichon, M., Jalfre, M. (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature, 266, 730-732.
36. Willner, P., Towell, A., Sampson, D., Sophokleous, S., Muscat, R. (1987) Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl.), 93, 358-364.
37. Pellow, S., Chopin, P., File, S.E., Briley, M. (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods, 14, 149-167.
38. Lister, R.G. (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl.), 92, 180-185.
39. Eisch, A.J., Petrik, D. (2012) Depression and hippocampal neurogenesis: a road to remission. Science, 338, 72-75.
40. Sahay, A., Drew, M.R., Hen, R. (2007) Dentate gyrus neurogenesis and depression. Prog. Brain Res., 163, 697-722.
41. Sahay, A., Hen, R. (2007) Adult hippocampal neurogenesis in depression. Nat. Neurosci., 10, 1110-1115.
42. Duan, W., Peng, Q., Masuda, N., Ford, E., Tryggestad, E., Ladenheim, B., Zhao, M., Cadet, J.L., Wong, J., Ross, C.A. (2008) Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis., 30, 312-322.
43. Fedele, V., Roybon, L., Nordstrom, U., Li, J.Y., Brundin, P. (2011) Neurogenesis in the R6/2 mouse model of Huntington's disease is impaired at the level of NeuroD1. Neuroscience, 173, 76-81.
44. Gil, J.M., Leist, M., Popovic, N., Brundin, P., Petersen, A. (2004) Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice. BMC Neurosci., 5, 17.
45. Gil, J.M., Mohapel, P., Araujo, I.M., Popovic, N., Li, J.Y., Brundin, P., Petersen, A. (2005) Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. Neurobiol. Dis., 20, 744-751.
46. Peng, Q., Masuda, N., Jiang, M., Li, Q., Zhao, M., Ross, C.A., Duan, W. (2008) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol., 210, 154-163.
47. Grote, H.E., Bull, N.D., Howard, M.L., van Dellen, A., Blakemore, C., Bartlett, P.F., Hannan, A.J. (2005) Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur. J. Neurosci., 22, 2081-2088.
48. Lazic, S.E., Grote, H., Armstrong, R.J., Blakemore, C., Hannan, A.J., van Dellen, A., Barker, R.A. (2004) Decreased hippocampal cell proliferation in R6/1 Huntington's mice. Neuroreport, 15, 811-813.
49. Lazic, S.E., Grote, H.E., Blakemore, C., Hannan, A.J., van Dellen, A., Phillips,W., Barker, R.A. (2006) Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur. J. Neurosci., 23, 1829-1838.
50. Simpson, J.M., Gil-Mohapel, J., Pouladi, M.A., Ghilan, M., Xie, Y., Hayden, M.R., Christie, B.R. (2011) Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiol. Dis., 41, 249-260.
51. Hannan, A.J., Ransome, M.I. (2012) Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice. J. Neuroendocrinol., 24, 341-356.
52. Ransome, M.I., Renoir, T., Hannan, A.J. (2012) Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington's disease. Neural Plast., 2012, 874387.
53. Christie, B.R., Cameron, H.A. (2006) Neurogenesis in the adult hippocampus. Hippocampus, 16, 199-207.
54. von Bohlen Und Halbach, O. (2007) Immunohistological markers for staging neurogenesis in adult hippocampus. Cell Tissue Res., 329, 409-420.
55. Bjorkqvist, M., Petersen, A., Bacos, K., Isaacs, J., Norlen, P., Gil, J., Popovic, N., Sundler, F., Bates, G.P., Tabrizi, S.J., et al. (2006) Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet., 15, 1713-1721.
56. Du, X., Leang, L., Mustafa, T., Renoir, T., Pang, T.Y., Hannan, A.J. (2012) Environmental enrichment rescues female-specific hyperactivity of the hypothalamic-pituitary-adrenal axis in a model of Huntington's disease. Transl. Psychiatry, 2, e133.
57. van Duijn, E., Selis, M.A., Giltay, E.J., Zitman, F.G., Roos, R.A., van Pelt, H., van der Mast, R.C. (2010) Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease mutation carriers compared with mutation-negative first-degree controls. Brain Res. Bull., 83, 232-237.
58. Bao, A.M., Meynen, G., Swaab, D.F. (2008) The stress system in depression and neurodegeneration: focus on thehumanhypothalamus. Brain Res. Rev., 57, 531-553.
59. Hult, S., Soylu, R., Bjorklund, T., Belgardt, B.F., Mauer, J., Bruning, J.C., Kirik, D., Petersen, A. (2011) Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab., 13, 428-439.
60. Kuhn, A., Goldstein, D.R., Hodges, A., Strand, A.D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M.A., Sathasivam, K., Cha, J.H., et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet., 16, 1845-1861.
61. Politis, M., Pavese, N., Tai, Y.F., Kiferle, L., Mason, S.L., Brooks, D.J., Tabrizi, S.J., Barker, R.A., Piccini, P. (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum. Brain Mapp., 32, 258-270.
62. Politis, M., Pavese, N., Tai, Y.F., Tabrizi, S.J., Barker, R.A., Piccini, P. (2008) Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain, 131, 2860-2869.
63. Bjorkqvist, M., Petersen, A., Nielsen, J., Ecker, D., Mulder, H., Hayden, M.R., Landwehrmeyer, B., Brundin, P., Leavitt, B.R. (2006) Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clin. Genet., 70, 78-79.
64. Scott, M.M., Marcus, J.N., Pettersen, A., Birnbaum, S.G., Mochizuki, T., Scammell, T.E., Nestler, E.J., Elmquist, J.K., Lutter, M. (2011) Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav. Brain Res., 222, 289-294.
65. Mikrouli, E., Wortwein, G., Soylu, R., Mathe, A.A., Petersen, A. (2011) Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. Neuropeptides, 45, 401-406.
66. Wu, G., Feder, A., Wegener, G., Bailey, C., Saxena, S., Charney, D., Mathe, A.A. (2011) Central functions of neuropeptideYinmoodand anxiety disorders. Expert Opin. Ther. Targets, 15, 1317-1331.
67. Eaton, K., Sallee, F.R., Sah, R. (2007) Relevance of neuropeptide Y (NPY) in psychiatry. Curr. Top. Med. Chem., 7, 1645-1659.
68. van Wamelen, D.J., Ahmad Aziz, N., Anink, J.J., Roos, R.A., Swaab, D.F. (2013) Neuropeptide alterations in the infundibular nucleus of Huntington's disease patients. J. Neuroendocrinol., 25, 198-205.
69. Jimenez-Vasquez, P.A., Diaz-Cabiale, Z., Caberlotto, L., Bellido, I., Overstreet, D., Fuxe, K., Mathe, A.A. (2007) Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. Eur. Neuropsychopharmacol., 17, 298-308.
70. Griebel, G., Holsboer, F. (2012) Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning. Nat. Rev. Drug Discov., 11, 462-478.
71. Navarro, V.M., Ruiz-Pino, F., Sanchez-Garrido, M.A., Garcia-Galiano, D., Hobbs, S.J., Manfredi-Lozano, M., Leon, S., Sangiao-Alvarellos, S., Castellano, J.M., Clifton, D.K., et al. (2012) Role of neurokinin B in the control of female puberty and its modulation by metabolic status. J. Neurosci., 32, 2388-2397.
72. Topaloglu, A.K., Reimann, F., Guclu, M., Yalin, A.S., Kotan, L.D., Porter, K.M., Serin, A., Mungan, N.O., Cook, J.R., Ozbek, M.N., et al. (2009) TAC3 andTACR3mutations in familial hypogonadotropic hypogonadism reveal a key role for NeurokininB in the central control of reproduction. Nat. Genet., 41, 354-358.
73. Fukui, M., Rodriguiz, R.M., Zhou, J., Jiang, S.X., Phillips, L.E., Caron, M.G., Wetsel, W.C. (2007) Vmat2 heterozygous mutant mice display a depressive-like phenotype. J. Neurosci., 27, 10520-10529.
74. Taylor, T.N., Caudle, W.M., Shepherd, K.R., Noorian, A., Jackson, C.R., Iuvone, P.M., Weinshenker, D., Greene, J.G., Miller, G.W. (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci., 29, 8103-8113.
75. Rogge, G., Jones, D., Hubert, G.W., Lin, Y., Kuhar, M.J. (2008) CART peptides: regulators of body weight, reward and other functions. Nat. Rev. Neurosci., 9, 747-758.
76. Wiehager, S., Beiderbeck, D.I., Gruber, S.H., El-Khoury, A., Wamsteeker, J., Neumann, I.D., Petersen, A., Mathe, A.A. (2009) Increased levels of cocaine and amphetamine regulated transcript in two animal models of depression and anxiety. Neurobiol. Dis., 34, 375-380.
77. Murphy, K.P., Carter, R.J., Lione, L.A., Mangiarini, L., Mahal, A., Bates, G.P., Dunnett, S.B., Morton, A.J. (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci., 20, 5115-5123.
78. Nithianantharajah, J., Barkus, C., Murphy, M., Hannan, A.J. (2008) Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol. Dis., 29, 490-504.
79. Pang, T.Y., Stam, N.C., Nithianantharajah, J., Howard, M.L., Hannan, A.J. (2006) Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. Neuroscience, 141, 569-584.
80. Van Raamsdonk, J.M., Pearson, J., Slow, E.J., Hossain, S.M., Leavitt, B.R., Hayden, M.R. (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci., 25, 4169-4180.
81. Southwell, A.L., Ko, J., Patterson, P.H. (2009) Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci., 29, 13589-13602.
82. Groves, M., van Duijn, E., Anderson, K., Craufurd, D., Edmondson, M.C., Goodman, N., van Kammen, D.P., Goodman, L. (2011) An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease. PLoS Curr., 3, RRN1259.
83. Gundersen, H.J.G. (1977) Notes on estimation of numerical density of arbitrary profiles-edge effect. J. Microsc., 111, 219-223.
84. Franklin, K., Paxinos, G. (2008) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
85. West, M.J. (1999) Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci., 22, 51-61.